Skip to Main Content

2,594

Views

3

CrossRef citations to date

0

Altmetric

Original Articles

Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor

Philipp Bernhard Stabera Clinical Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, AustriaCorrespondence[email protected]
View further author information

,

Wojciech Jurczakb Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, PolandView further author information

,

Richard Greilc Laboratory for Immunological and Molecular Cancer Research, Salzburg Cancer Research Institute, Salzburg, AustriaView further author information

,

Vladan Vucinicd Department of Hematology and Internal Oncology, University Hospital Leipzig AöR, Leipzig, GermanyView further author information

,

Jan Moritz Middekee Medical Clinic 1, University Hospital Carl Gustav Carus, TU Dresden, Dresden, GermanyView further author information

,

Marco Montillof Hematology Department, Niguarda Cancer Center, Niguarda Hospital, Milan, ItalyView further author information

,

Talha Munirg Clinical Hematology, The Leeds Teaching Hospital, Leeds, UKView further author information

,

Peter Neumeisterh Clinical Department of Hematology, Medical University of Graz, Graz, AustriaView further author information

,

Johannes Schetelige Medical Clinic 1, University Hospital Carl Gustav Carus, TU Dresden, Dresden, GermanyView further author information

,

Stephan Stilgenbaueri Department of Internal Medicine III, Ulm University, Ulm, GermanyView further author information

,

Frank Striebelj MorphoSys AG, Planegg, GermanyView further author information

,

Maren Dirnberger-Hertweckj MorphoSys AG, Planegg, GermanyView further author information

,

Johannes Weiratherj MorphoSys AG, Planegg, GermanyView further author information

,

Wolfram Bruggerj MorphoSys AG, Planegg, GermanyView further author information

,

Peter Kelemenj MorphoSys AG, Planegg, GermanyView further author information

,

Clemens-Martin Wendtnerk Department of Hematology, Oncology, Immunology, Palliative Medicine, Infectious Diseases, and Tropical Medicine, Munich Clinic Schwabing, Munich, GermanyView further author information

&

Jennifer Ann Woyachl Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus, OH, USAView further author information